ERBB2 and neoplasm: HSP90, Her2 expression and Her2 status according to FDA and EMEA were associated with lower local tumor burden, absence of lymph node metastases, better tumor differentiation (grading), and intestinal phenotype according to Lauren (p values see Tables 4 and 5).